Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Clin Interv Aging. 2009;4:207-14. Epub 2009 May 14.

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

Author information

  • Division of Rheumatology, Beth Israel Medical Center, New York, NY 10003, USA. prackoff@chpnet.org

Abstract

Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.

KEYWORDS:

fracture, osteoporosis

PMID:
19503783
[PubMed - indexed for MEDLINE]
PMCID:
PMC2685242
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk